Idogen AB (publ) announced that the company receiving the Swedish Medicines Agency's approval of its clinical phase 1/2a study for IDO 8, a completely new type of cell therapy for patients with severe hemophilia A who have developed antibodies to its vital treatment with coagulation factor VIII. The purpose of IDO 8 is to create tolerance for and enable continued treatment with factor VIII. The clinical study has been designed in close dialogue with leading specialists in coagulation disorders and regulatory authorities in the Nordic region with the aim of evaluating the safety of IDO 8 and following signals of treatment effect in patients.